MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.76
+0.06
+0.78%
After Hours: 7.76 0 0.00% 16:41 04/08 EDT
OPEN
7.95
PREV CLOSE
7.70
HIGH
8.00
LOW
7.47
VOLUME
507.61K
TURNOVER
--
52 WEEK HIGH
40.25
52 WEEK LOW
4.520
MARKET CAP
454.52M
P/E (TTM)
-1.3598
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATRA stock price target is 28.50 with a high estimate of 70.00 and a low estimate of 8.00.

EPS

ATRA News

More
  • More COVID-19 actions - healthcare
  • seekingalpha · 6d ago
  • Atara Biotherapeutics Says Remains On Track To Initiate tab-cel Biologics License Aplpication Submission For Patients With EBV+ PTLD In H2'20
  • Benzinga · 6d ago
  • Company Profile for Atara Biotherapeutics, Inc.
  • Business Wire · 6d ago
  • Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic
  • Business Wire · 6d ago

Industry

Biotechnology & Medical Research
+3.08%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About ATRA

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
More

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.